NCT00731653 - Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

January 31, 2009

Conditions

Major Depressive Disorder

Interventions

DRUG

Combination Product: BCI-024 + BCI-049

BCI-024 and BCI-049 once a day at bedtime for 6 weeks

Trial Locations (9)

CRI Worldwide, Philadelphia

Capital Clinical Research Associates, Rockville

Atlanta Institute of Medicine & Research, Inc., Altanta

NorthCoast Clinical Trials, Beachwood

FutureSearch Trials of Dallas, L.P., Dallas

Claghorn-Lesem Research Clinic, Ltd., Houston

FutureSearch Clinical Trials, L.P., Austin

Synergy Research Centers, San Diego

Collaborative Neuroscience Network, Inc., Garden Grove